top of page

Top pharmaceutical companies by revenues in 2024 | Big Pharma | Top Pharma profits | iPharmaCenter

TOP PHARMACEUTICAL COMPANIES BY REVENUES IN 2024






1. JOHNSON AND JOHNSON

Q1 REVENUES:

In the first quarter of 2024, Johnson & Johnson reported sales growth of 2.3%, reaching $21.4 billion. The operational growth was 3.9%, and the adjusted operational growth (excluding COVID-19 Vaccine impact) stood at 4.0%. Notably, adjusted operational growth, excluding the vaccine, was an impressive 7.7%.


Best selling drugs



2. ROCHE

Q1 RESULTS:

  • Sales Decline: In the first quarter of 2024, Roche reported a 6% decline in sales, amounting to 14.4 billion Swiss francs (approximately $15.80 billion). This decrease was attributed to the impact of foreign exchange rates and the loss of revenue from COVID-related products.

  • Pharmaceutical Division: The pharmaceutical division’s performance also slowed, with sales dropping to $11.96 billion from $12.71 billion in the same period last year.

Pfizer reported total revenues of $14.9 billion for Q1 2024.


Eliquis

$2.0 billion

Paxlovid

$2.0 billion

Ibrance

$1.0 billion


AbbVie delivered first-quarter net revenues of $12.310 billion, showing a modest increase of 0.7% on a reported basis and 1.6% on an operational basis.

Humira

$2.3 billion

Skyrizi

$2.0 billion

Rinvoq

$1.0 billion


5. MERCK

Q1 RESULTS:

Merck reported continued strong growth in oncology and vaccines. Total worldwide sales for Q1 2024 were $14.0 billion.

Keytruda revenues were $6.9 billion, an increase of 20% revenues compared to previous year.

Keytruda

$14.0 billion

Gardasil/Gardasil 9

$2.2 billion




Q1 REVENUES

Sanofi achieved a 6.7% sales growth at constant exchange rates (CER), with net sales totaling $12.4 billion. Dupixent revenues were $3.4 billion, and expected revenues were $14.0 billion.


7. NOVARTIS

Sales Growth: The company reported a 25% increase in net income from continuing operations, reaching $2.68 billion compared to $2.15 billion in Q1 2023.






8. ASTRAZENECA


In the first quarter, Bristol Myers Squibb reported revenues of $11.9 billion, marking a 5% increase, or 6% when accounting for foreign exchange effects. This growth was primarily fueled by strong performances from Eliquis, Reblozyl, and Opdualag, although somewhat tempered by declines in Opdivo and Revlimid sales.


In the U.S., revenues rose by 7% to $8.5 billion, driven by the success of Eliquis, Reblozyl, and Opdualag, offsetting declines in Revlimid. Opdivo revenues saw a decrease from $1.3 billion to $1.2 billion, down by 10%, mainly due to inventory adjustments and timing of orders, despite underlying demand growth.


Meanwhile, international revenues remained relatively steady at $3.4 billion, as increased demand for Opdivo, Yervoy, and Reblozyl offset lower selling prices. Foreign exchange fluctuations had a 5% adverse impact on revenues.


Top pharmaceutical companies by revenues in 2024 | big pharma profits
Top pharmaceutical companies revenues 2024

0 comments

Recent Posts

See All

Australia Healthcare News | Media | Updates

New medications, Jemperli and Korsuva will be available for endometrial cancer and chronic kidney disease For women facing advanced or recurring endometrial cancer, a medication called Jemperli (dosta

Comments


bottom of page